Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s biosimilar from the U.S. Two investigational eye therapies, from Opthea Limited and ...

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...